Events

Unexpected particle findings can raise critical questions about product quality, patient safety, and regulatory compliance. Join KBI Biopharma's experts to learn how clinical in-use studies and advanced particle forensics can help identify particle sources, assess risk, and build regulator-ready evidence for confident decision-making. Register now to discover practical strategies for accelerating investigations, supporting development timelines,...

As biologics developers work to improve productivity, maintain product quality, and accelerate development timelines, traditional optimization approaches can sometimes reach a point of diminishing returns. While cell culture processes generate vast amounts of biological and process data, extracting actionable insights from that information remains a significant challenge. In this webinar, Thermo Fisher Scientific specialists discuss...

As biologics developers work to improve productivity, reduce development timelines, and manage manufacturing costs, traditional media optimization approaches can become increasingly resource intensive. Predictive modeling is emerging as a complementary approach that can help integrate biological knowledge, process data, and artificial intelligence (AI) to support more efficient media development. In this webinar, Thermo Fisher Scientific...

Nanoparticle programs can stall when early formulation choices fail to hold up through scale-up, tech transfer, and manufacturing. Join leading CDMO experts on August 18 at 11:00 AM ET to learn how decisions around lipid or polymer selection, particle engineering, process design, and manufacturability can impact downstream success. Register now to gain practical insights that...

Oral solid dose programs can run into costly scale-up challenges when early formulation and process decisions aren’t built for long-term manufacturability. Join leading CDMO experts on August 18 at 1:00 PM ET to explore how excipient selection, granulation strategy, particle engineering, and process design can impact tech transfer, validation, and commercial manufacturing. Register now to...

In this webinar we expand on some of the processes most vulnerable to introducing titer variability, as well as strategies to overcome sources of variability when they are unavoidable to maintain high-titer production.

How can life sciences companies developing new medicines engage the FDA successfully during a period of rapid changes in agency personnel and policies? Should companies adjust their agency communication strategies or ask new questions during meetings? Our deeply experienced panelists will discuss key changes at the FDA, how companies can get the most out of...

Join Dr. Marco Davila to explore a novel anti-CD83 CAR-T design for relapsed/refractory AML that overcomes myelosuppression barriers. Register for the live session. Developing effective Chimeric Antigen Receptor (CAR) T-cell therapies for Acute Myeloid Leukemia (AML) remains one of the most formidable frontiers in cellular immunotherapy. Unlike lymphoid malignancies where lineage-specific targets like CD19 or...

Explore how leading teams are using trusted data and targeted AI to design, plan, and execute trials with the confidence today's science requires. Learning outcomes: - Understand what's driving trial complexity - Design protocols with confidence using real data + AI - Select sites based on holistic drivers of outcomes; access, experience and past performance...